New hormone therapy shows promise for rare calcium disorder
NCT ID NCT05239221
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 34 times
Summary
This study tested a new synthetic parathyroid hormone analog (AZP-3601) in healthy volunteers and patients with chronic hypoparathyroidism, a condition where the body doesn't produce enough parathyroid hormone. The main goal was to check safety and how the drug moves through the body. The study involved 132 participants and included single and multiple doses over up to 3 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HYPOPARATHYROIDISM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Amolyt Pharma Investigational Site Hungary
Budapest, Hungary
-
PRA-EDS
Groningen, 9728, Netherlands
Conditions
Explore the condition pages connected to this study.